Kalaris Therapeutics, Inc. (KLRS)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20261 patent granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Kalaris Therapeutics, Inc.’s names, not what it holds today.
1 published
0 published
| Granted | Patent | Title | Field | Owner as printed |
|---|---|---|---|---|
| Apr 23, 2024 | 11,963,979 | Process for T cell expansion | Pharmaceuticals | AlloVir, Inc. |
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| May 19, 2022 | 2022/0152111 | PROCESS FOR T CELL EXPANSION | Pharmaceuticals | AlloVir Inc. |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.